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A Human Single-Chain Antibody Specific for
Integrin 31 Capable of Cell Internalization
and Delivery of Antitumor Agents
gands [9, 10]. This line of research presents opportuni-
ties to use protein vectors to deliver drug payloads that
can increase the efficacy and lessen side effects of
cancer chemotherapy. One demonstration of the clinical
potential for such a strategy invoked the cell internaliz-
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Medicine ceptor, is expressed by both fetal and adult tissues
mediating adhesive, migratory, and invasive cell interac-The Scripps Research Institute and
The Skaggs Institute for Chemical Biology tions with the extracellular matrix [12]. Elevated expres-
sion of 31 has been observed in several types of meta-10550 North Torrey Pines Road
La Jolla, California 92037 static cancer types and has been associated with
increased migration and invasion. Notably, expression
of this integrin is upregulated in malignant melanoma
and correlates well with the degree of migration andSummary
dermal invasiveness [13–16]. The 31 integrin is also
expressed by invasive clones of human PC-3 prostateSelective antitumor chemotherapy can be achieved by
carcinoma cells, but not by the noninvasive parent cellusing antibody-drug conjugates that recognize sur-
population [17, 18]. Similarly, the invasive properties offace proteins upregulated in cancer cells. One such
different squamous cell cancers have been correlatedreceptor is integrin 31, which is overexpressed on
to overexpression of several integrins including 31 [19,malignant melanoma, prostate carcinoma, and glioma
20]. It has also been shown that functional inhibition ofcells. We previously identified a human single-chain
31 in malignant glioma cells can block their invasiveFv antibody (scFv), denoted Pan10, specific for integrin
ability [21]. The 31 is also associated with mammary31 that is internalized by human pancreatic cancer
carcinoma cell metastasis, invasion, and collagen deg-cells. Herein, we describe the chemical introduction
radation activity [22]. Finally, expression of 31 in mu-of reactive thiol groups onto Pan10, the specific conju-
rine hepatocellular carcinoma (HCC) has been associ-gation of the modified scFv to maleimide-derivatized
ated with the occurrence of intrahepatic metastasis,analogs of the potent cytotoxic agent duocarmycin
which is considered to be a major modality in recurrenceSA, and the properties of the resultant conjugates. Our
[23]. Given the often distinct levels of expression be-findings provide evidence that Pan10-drug conjugates
tween malignant cancer cells and normal cells, 31 canmaintain the internalizing capacity of the parent scFv
be considered a viable target for a specific antibody-and are cytotoxic at nanomolar concentrations. Our
based antineoplastic treatment designed to kill cancerPan10-drug conjugates may be promising candidates
cells and control metastatic dissemination.for targeted chemotherapy of malignant diseases as-
Selective control of metastasis by targeting 31 hassociated with overexpression of integrin 31.
been shown to be successful in the treatment of intrahe-
patic metastasis of HCC using an RGD (Arginine-Gly-
Introduction cine-Aspartate) pseudopeptide [23]. Also, squamous
cell carcinoma of the head and neck has been treated
Targeted treatment of tumors has advanced consider- by selective gene delivery via an 31 integrin-targetedably in the last two decades, primarily due to the estab- adenoviral vector [24]. Several murine mAbs are known
lishment of monoclonal antibody (mAb) technology [1]. to target either the 3 or 1 subunits of 31 [25–27];An early fundamental application was the development however, none are known to be internalized by tumor
of radiolabeled mAbs, some of which have attained clini- cells nor have they ever been used as anticancer thera-
cal use for imaging and cancer therapy [2, 3]. Signifi- peutics. Significantly, the typical murine origin of most
cantly, mAb-drug conjugates are another potential class mAbs is a detriment for human clinical application [28–
of anticancer agents that have been extensively investi- 31]. In addition, another barrier can be the effective use
gated [4–6]. However, although isolated examples of of a mAb as whole immunoglobulin G (IgG), generally
success have been reported, considerable advances attributed to the high molecular weight, which hinders
are necessary in order to address the complex issue of efficient penetration of solid tumors. For instance, stud-
cancer treatment. ies have indicated that less than 1% of an infused radio-
A central goal in our laboratory as well as other groups labeled IgG can reach its target tumor mass [32, 33].
[7, 8] has been the search for human mAbs or peptides One method to circumvent this problem is the use of a
that can be specifically internalized by tumor cells upon mAb in the scFv format. Compared to whole IgG and
binding to overexpressed cell surface receptors or li- the fragments Fab and F(ab)2, scFvs have been shown
to permeate more rapidly and deeper into tumors in
addition to demonstrating very rapid plasma and body*Correspondence: kdjanda@scripps.edu
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clearance (30 min) [34–38]. Therefore, in many cases, Results and Discussion
a preferred therapeutic strategy may be the use of a
human scFv conjugated with an anticancer agent. Pan10 Expression, Purification,
CC-1065 [39] and duocarmycin [40, 41] are two antitu- and Site-Directed Mutagenesis
mor antibiotics [42] possessing sequence-selective To use Pan10 as a tool for the delivery of duocarmycin
DNA alkylation properties [43]. The development of analogs to malignant cancer cells, phage-free Pan10
these anticancer molecules for single-agent therapies was expressed as a scFv of 27,868 kDa (Table 1) and
has not been pursued because of delayed toxicities purified to homogeneity (Figure 2, lane 4). Since typical
that limit the therapeutic dose range for treatment. For VL and VH domains each possess a buried single disulfide
instance, despite its high potency and broad spectrum linkage [52], but no free cysteines, we investigated sev-
of antitumor activity, CC-1065 can not be used in hu- eral strategies intended to make available free thiol
mans because it has been shown to cause delayed groups on the surface of Pan10 and to conjugate the
death in experimental animals [39]. However, these modified scFv to maleimide-derivatized drugs.
drugs may be well suited for antibody-targeted chemo- Our initial approach was aimed at single site-specific
therapy, where restricted antigen expression makes the conjugation using a cysteine incorporated into the wild-
potency of the cytotoxic agent crucial and targeting can type Pan10 sequence by site-directed mutagenesis. In
avert some toxic effects [44, 45]. Great efforts have been an attempt to preserve the scFv binding affinity, we first
made to specifically target the high cytotoxicity of these looked at introducing the cysteine residue into the linker
compounds to the tumor mass sparing normal healthy region of Pan10. Additionally, a commercially available
cells. Investigations have included tumor-activated pro- maleimide-derivatized fluorescein (FM) was used as a
drug (TAP) [46, 47] and antibody-directed enzyme pro- sensitive reagent to optimize and quantify conjugation
drug therapy (ADEPT) [48–50] approaches. Both meth- protocols. When any one of the linker residues S131,
ods are intended to reduce the cytotoxicity of CC-1065 G130, G128, or G127 (see Supplemental Figure S1) were
or duocarmycin analogs by conjugating these molecules mutated to cysteine, the efficiency of conjugation of the
to substrates of enzymes at the tumor site. In the first mutants with FM was only similar to the wild-type Pan10.
study, the targeted enzyme was naturally present in the We attributed this result to the linker region and cysteine
tumor environment, while in the second study, the en- residue being sequestered within the Pan10 structure.
zyme was brought to the tumor site upon conjugation Therefore, we turned our attention to several other resi-
to a tumor-specific antibody. Despite their elegance, the
dues, which according to a web antibody modelling
main drawbacks of these approaches are the residual
(WAM c/o University of Bath at Swindon, Oakfield Cam-
cytotoxicity of the prodrugs and the release of the free
pus, Marlowe Avenue, Walcot Swindon Wilts, Uniteddrug outside the tumor cell. To date, no attempts to
Kingdom) theoretical structure of Pan10 appeared to bedeliver duocarmycin analogs specifically into tumor
surface exposed. To preserve the tumor cell bindingcells by conjugating this drug to antibody fragments
and internalizing ability of Pan10, only framework resi-have been reported.
dues were considered. Improved FM conjugation wasWe previously described the biopanning of a human
achieved when the more exposed residues S73 or S197scFv-phage display library based on the selection re-
were mutated, confirming our rationale about the inac-quirement of internalization by the SW1990 human
cessibility of the linker residues. Nevertheless, the effi-pancreatic adenocarcinoma cell line [9]. Our efforts pro-
ciency of conjugation achieved was at best 68% (Sup-duced a scFv, denoted Pan10, which upon immunopre-
plemental Table S1), which we hypothesize was due tocipitation, mass spectrometric analysis, and database
oxidation or dimerization of the introduced cysteines.searching was found to target membrane receptor integ-
rin 31. Because of the specific Pan10 interaction with
31 and the internalization capability, we viewed this
Chemical Modification of scFv Pan10scFv as a vector for conjugation with potent duocar-
Insertion of free cysteines by site-directed mutagenesis,mycin-SA analogs 3-(5-acetylindole-2-carbonyl)-1-(S )-
while elegant, presents several drawbacks. First, if the(chloromethyl)-5-hydroxy-1,2-dihydro-3H-benz[e]in-
mutated residue is solvent accessible it will likely un-dole [51] (compound 1, Figure 1) and 3-[5-(1-(3-amino-
dergo oxidation or induce dimerization. Thus, an addi-propyl)indole-2-carbonyl)aminoindole-2-carbonyl]-1-
tional reduction-purification step is needed, and the(chloromethyl)-5-hydroxy-1,2-dihydro-3H-benz[e]
subsequent reactions must be carried out in an inertindole (compound 2, Figure 1) to promote the destruc-
atmosphere as previously reported [53]. To solve thistion of malignant tumor cells overexpressing integrin
dilemma, we examined the chemical addition of thiol31. Hence, our initial efforts focused upon a number
groups onto Pan10. In our initial approach, the thiolationof challenging tasks, including: (1) the conjugation of
and the conjugation to maleimide-derivatized moleculesantitumor drug(s) to scFv Pan10 without compromising
were performed in two separate steps. In the first step,target affinity and internalization properties; (2) the de-
the free thiol groups were introduced by reacting Pan10sign of linkers promoting efficient attachment of the
with 2-iminothiolane (Traut’s reagent), an amine scaven-drug(s) to the scFv without compromising the cytotoxic
ger that reacts with lysine residues. We were aware ofactivity of the drug(s); and (3) the search for a reliable
the fact that the presence of twelve lysines in the Pan10cell-based assay designed to evaluate the biological
sequence might have led to a massive and potentiallyactivity of Pan10-drug conjugates. We believe that the
harmful modification. However, we were encouraged byresults herein are an important step toward the thera-
knowing that ten of those lysines were in the frameworkpeutic application of scFv-mediated, tumor-targeted
delivery of anticancer compounds. regions (Supplemental Figure S1), and therefore, their
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Figure 1. Duocarmycin SA, CBI Indole Ana-
logs, and Maleimide Derivatives
modification would unlikely affect Pan10 binding to in- merization. A further improvement was obtained with
the use of a one-step procedure, where thiolation andtegrin 31. Our expectations were confirmed, as whole-
cell enzyme-linked immunosorbent assay (ELISA) re- conjugation occurred in one pot. SDS-PAGE analysis
of Pan10 modified using this method revealed only avealed that binding of wild-type Pan10 and thiolated
Pan10 were virtually indistinguishable. However, nonre- negligible formation of dimers (Figure 2A, lane 3). We
anticipate this procedure to be of general use with otherducing sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) analysis of the thiolated Pan10 scFvs (vide infra).
(Figure 2) revealed time-dependent formation of dimers
and higher polymers (Figure 2A, lane 2), which caused a Maleimide-Derivatized Drugs
The maleimide moiety was attached to duocarmycin SAprogressive reduction of the number of free thiol groups
available for drug conjugation. In order to avoid this analog 1 via an acid-labile hydrazone linkage to give the
maleimide derivative 3 (Figure 1). The hydrazone linkageproblem, we attempted to perform the subsequent drug
conjugation step immediately after thiolation. This strat- method is widely utilized in antibody-drug conjugates
as a way of controlled release of the cytotoxic drugegy improved the coupling efficiency and reduced di-
Table 1. Results of Mass Spectrometry Analysis
Calculated Experimental Molar Ratiosa
Analyte MW (g/mol) Mass (m/z) (Pan10:FM/drug-maleimide)
Pan10 27610 27868 –
Pan10-FM 28216 28388 0.997
Pan10-3 28297 28634 1.003
Pan10-4 28456 28545 0.994
a Measured from MR  (MWconjugate  MWPan10)/MWFM/ drug-maleimide using MALDI-measured MWs.
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Figure 2. SDS-PAGE Analysis of Purified Pan10 and Pan10 Conju-
gates
(A) SDS-PAGE gel slab. Lane 1, Invitrogen prestained markers; lane
2, Pan10 after separate thiolation and conjugation; lane 3, Pan10
after one-pot thiolation and conjugation; lane 4, unmodified Pan10.
(B) Bands density analysis (AlphaEaseFC StandAlone Software). The
shaded boxes contain data relative to the band corresponding to
the monomeric scFv in each lane.
upon internalization into lysosomes where the pH value
is slightly lower (pH  5.0–5.5) than in the cytosol [54]. Figure 3. Confocal Microscopy, Overlaid 488 nm and 568 nm Im-
This strategy has proven to be clinically effective in many ages of SW1990 and HdFa Cells Treated with Pan10-FM
instances, such as in the development of BR96-DOX by (A) SW1990 cells after 2 hr incubation, (B) HdFa cells after 2 hr, (C)
SW1990 cells after 3 hr, and (D) HdFa cells after 3 hr.Bristol-Myers Squibb and the design of Mylotarg by
Wyeth. As a comparison, we derivatized the Boc-pro-
tected duocarmycin analog 2 (compound 10, Figure 5)
cific antibody 92H2 [55]), affording a maximum ratio ofthrough a pH-insensitive amide bond linkage, producing
fluorescein:protein of 3:1 without loss of antigen bindingthe maleimide derivative 4 (Figure 1).
activity (data not shown). Therefore, we believe that such
a conjugation method might be applicable to a vastPan10 Conjugation to Maleimide-Derivatized
array of scFvs.Molecules
As noted above, thiolated Pan10 was initially conjugated
to FM to give Pan10-FM in order to test and directly Biological Activity of Pan10 Conjugates
Several methods were employed to explore the biologi-visualize internalization by pancreatic cancer cells. Sub-
sequently, we conjugated the thiolated Pan10 to malei- cal activity of our Pan10 conjugates. Confocal micros-
copy analysis was used to investigate the specificity ofmide derivatives 3 and 4 obtaining conjugates Pan10-3
and Pan10-4, respectively. The ratio of either fluorescein the interaction of the Pan10-FM with SW1990 cells ver-
sus the normal human dermal fibroblast cell line (HdFa).(conjugation efficiency measured by UV/Vis spectrome-
try and matrix-assisted laser desorption/ionization mass Our results showed that Pan10-FM was internalized by
SW1990 cells in a time-dependent fashion (Figure 3).spectrometry [MALDI-MS]) 3 or 4 (conjugation efficiency
measured by MALDI-MS) to Pan10 was found to be Moreover, after the second hour of incubation, internal-
ization in these cancerous cells was much more pro-approximately 1:1 using our two-step coupling proce-
dure (Table 1). On the other hand, when conjugation and nounced than in noncancerous HdFa. These findings
confirm that the Pan10-FM conjugate retains the wild-thiolation were performed in a single step, the ratio of
fluorescein to Pan10 was 2:1 (conjugation efficiency type activity of Pan10 and provide evidence that in pan-
creatic cancer cells the overexpression of integrin 31measured by UV/Vis spectrometry only). We believe that
this difference in conjugation efficiency is due to the allows some selectivity versus HdFa used as a model
for a noncancer cell type.polymerization of the thiolated Pan10 in the absence of
thiol-quenching small molecules. Indeed, several addi- SW1990 cells treated with Pan10, Pan10-FM, Pan10-3,
or Pan10-4 were examined by inverted microscopy fortional higher molecular weight species were detected
by SDS-PAGE (Figure 2) and size-exclusion chromatog- a qualitative determination of the effect of the drug con-
jugates on the cell viability. After 7 days in culture, theraphy (Supplemental Figure S2) of Pan10-drug conju-
gates obtained in two separate steps. cells treated with Pan10 or Pan10-FM had expanded
into healthy colonies, whereas the cells treated withOur one-pot scFv conjugation method has been
tested on other scFvs (v3-specific antibodies Bc-12 Pan10-drug conjugates had either died or showed ex-
cessive vacuolization, indicating advanced apoptosisand Bc-15 [B.F.-H. et al., submitted] and cocaine-spe-
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Figure 4. Inverted Microscope Images of
SW1990
(A) Untreated cells. (B) Cells treated with
Pan10-FM. (C) Cells treated with Pan10-4. (D)
Cells treated with Pan10-3. The enlarged im-
ages of two of the cells treated with scFv-
drug conjugates show extensive vacuoli-
zation.
(Figure 4). The cytotoxic effect of the Pan10-drug conju- 2) were two to three orders of magnitude higher than
gates in comparison with the toxicity of the free drugs the previously obtained values (2  30 pM [51] and 1 
was then quantified by the MTT (3-(4,5-dimethylthiazol- 2 pM [obtained as for 2]). This inconsistency is probably
2-yl)-2,5,-diphenyltetrazolium bromide) cell proliferation due to a difference in the cell line used, duration of drug
assay [56–58]. SW1990 pancreatic carcinoma cells were exposure, and cytotoxicity assay chosen. In our study,
seeded and allowed to attach in growth medium over- the free drugs had a more potent cytotoxic effect than
night. The cultures were then treated for either 3 or 12 the corresponding Pan10-drug conjugates, especially
hr with increasing concentrations of free drugs or after a short exposure time. We attribute this effect to
Pan10-drug conjugates. After 7 days, the number of a more immediate availability of the free drug in the
viable cells indicated a clear cytostatic/cytotoxic effect nucleus, where DNA is the site of action, upon diffusion
of Pan10-drug conjugates, especially after the 12 hr through the plasma and nuclear membranes. Further
drug exposure time (Table 2). The inhibitory concentra- evidence in support of this hypothesis came from the
tion 50% (IC50) values measured for the free drugs (Table observation that the difference in efficacy between free
drug and Pan10-drug conjugate was significantly re-
duced when the incubation time was extended. In partic-
Table 2. Results of MTT Assay on SW1990 Cells ular, after a 12 hr incubation period, the Pan10-4 conju-
gate was as effective as the free compound 2.Cytotoxic Agent IC50 (nM) IC50 (nM)d
Interestingly, Pan10-3 (scFv:drug  1:1) displayed a
1 1.4  0.2b 0.43  0.17
cytotoxicity similar to Pan10-4 (scFv:drug  1:1). ThisPan10-3 (1:1)a 94.3  3.6c 2.7  0.3
result, together with the lower cytotoxicity observed forPan10-3 (1:2)a 251.3  75.8b 22.6  3.8
conjugates carrying two drug molecules per molecule2 32.1  13.1b 4.3  0.2
Pan10-4 (1:1)a 97.9  38.6c 4.4  0.7 of scFv, suggests that in our case there is no advantage
Pan10-4 (1:2)a 1528  369.4b 180.8  30.6 in derivatizing the drug through the hydrazone linkage.
The results also imply that the mechanism of endocyto-a Ratio scFv to drug.
b Average of four experiments. Three hour incubation with drug. sis of the Pan10 conjugates may not involve transfer
c Average of two experiments. Three hour incubation with drug. into a low-pH environment and that upon cell internaliza-
d Average of two experiments. Twelve hour incubation with drug.
tion the drug remains linked either to the intact Pan10
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or to peptides derived from the intracellular proteolysis conjugates show excellent cytotoxic effects on pan-
creatic carcinoma cells in vitro. This first step is ofof Pan10. The residual activity of such hypothetical com-
plexes would not be surprising, since the tether we used critical importance considering the unique advantage
of the scFv conjugates compared to the free drugsbetween the scFv and the drug is probably long enough
to allow for interaction with the DNA target and preserva- described herein, which are extremely potent but not
clinically viable anticancer agents. The conjugates cantion of cytotoxicity. Indeed, a conjugate in which drug
release from the scFv/scFv-derived peptides is not re- deliver these drug molecules more specifically to the
interior of cancer cells overexpressing integrin 31,quired for cytotoxic action could be advantageous, par-
ticularly within the context of a cell internalization mech- which should allow for reduced therapeutic drug expo-
sure and enhanced efficacy. Using such a strategy,anism. In this way, the scFv/peptide-drug compared to
free drug might be trapped more effectively within the experiments continue in our laboratory to further elab-
orate the potential for scFv-drug designs in cancercell through reduced passive (diffusional) and active ef-
flux processes. Overall, this mechanism would lead to treatment.
the time-dependent accumulation of high intracellular
concentrations of drug, affording the potential for effi- Experimental Procedures
cient cancer cell killing, an excellent therapeutic index,
Expression and Purification of Pan10and a decreased likelihood of acquiring drug resistance.
E. coli B834(DE3) (Novagen, Madison, WI) was selected as the ex-Finally, in testing the Pan10-3 and the Pan10-4 conju-
pression host for transformation with plasmids pETflag-Pan10 [59].
gates on the normal HdFa cells, cytotoxicity was ob- E. coli B834(DE3)/pETflag-Pan10 were grown in SB medium (30%
served with an IC50 3- and 5-fold higher, respectively, peptone, 20% yeast extract, 10% MOPS) supplemented with 100
than those against the SW1990 cancer cells, whereas M carbenicillin (RPI Corp., Mount Prospect, IL) at 37	C to mid-log
phase (OD600 0.65). Protein expression was induced by addition ofthe free 1 had roughly the same IC50 values against both
0.5 mM IPTG (RPI Corp.). The cultures were incubated for an addi-cells lines (data not shown). We had perhaps anticipated
tional 1 hr at 37	C and for 15 hr at 26	C. A 4 L culture of IPTG-induceda greater cytotoxic specificity with the Pan10-drug con-
E. coli B834/pETflag-Pan10 was harvested by centrifugation. The
jugates. Yet, there may be a correlation between the resultant cell pellet was lysed using BugBuster Protein Extraction
result and a measurement by fluorescence-activated Reagent (Novagen) according to the vendor’s instructions, while the
cell sorting (FACS) that showed a 5-fold greater level of supernatant was concentrated to 200 ml (EasyLoad, Masterflex
from Millipore, Bedford, MA). Upon filtration through a 0.2 M filter3 integrin expression on SW1990 cell compared to
(Nalgene, Rochester, NY), the cell-free lysate (100 mL) or the con-HdFa cells (Supplemental Table S2). However, we em-
centrated supernatant was loaded at a flow rate of 1 mL/min ontophasize that the value of such comparisons and correla-
an Anti-Flag M2 affinity column (1.7 
 5 cm from Sigma, St. Louis,
tions is difficult to assess, especially given the differ- MO) previously equilibrated with phosphate-buffered saline (PBS).
ences between the two cell types and the in vitro After washing with 100 ml of PBS, the flag-tagged Pan10 was eluted
conditions of cell growth and analysis. Moreover, the from the column with 20 ml of glycine buffer (0.1 M glycine [pH
2.5]) at a flow rate of 3 mL/min. The eluate was neutralized with 1cell-killing experiments were primarily intended to as-
mL 1 M Tris Base. The level of purity was assessed by SDS-PAGEsess maintenance of internalization and drug activity of
(10% Bis-Tris from Bio-Rad, Hercules, CA). A 4 L culture of IPTG-the Pan10-drug conjugates as evidenced by cytotoxic-
induced E. coli B834(DE3)/pETflag-Pan10 usually afforded 3.5–5 mg
ity, and not intended to be indicative of what might of purified protein, 60% of which was derived from the cell pellet.
transpire in vivo. In particular, even the incubation condi-
tions and the use of IC50 values can be considered artifi- Cell Lines
cial parameters to demonstrate efficacy. A scFv-drug The human pancreatic adenocarcinoma cell line SW1990 (ATCC,
would be cleared rapidly from the body, and IC50 is a Manassas, VA) was grown in Leibovitz’s L-15 medium supplemented
with 10% fetal calf serum (FCS). The normal human dermal fibro-thermodynamic parameter under essentially equilibrium
blasts (HdFa) from adult skin (Cascade Biologics, Portland, OR)conditions. Drug administration and activity in vivo will
were grown in Medium 106 supplemented with low-serum growthbe a more kinetically controlled and dynamic process
supplement.
in which infusion conditions and dosing can be manipu-
lated to better exploit the internalization and accumula-
SW1990 Binding Assay by Whole-Cell ELISAtion of the scFv-drug conjugate in tumor cells. Hence,
SW1990 cells were trypsinized and resuspended in PBS to a concen-
it might not be necessary to even approach adminis- tration of 106 cells/mL. Aliquots (150 L) were poured in the wells
tered or systemic IC50 concentrations observed in vitro, of a 96-well ELISA plate (tissue culture treated, flat bottom from
Corning Incorporated, Canton, NY) and incubated at 37	C to com-which would allow enhanced tumor specificity and re-
plete evaporation (note that two rows of wells contained mediumduced side effects. In the current example, a more valid
only). The plate was then washed four times with 0.025% Tween 20test for our Pan10-drug conjugates will be in subsequent
(Sigma, St. Louis, MO) in PBS, blocked with 1% bovine serum albu-animal models.
min (BSA from Sigma) in PBS, washed once with deionized water,
and pat-dried. Aliquots (100 L) of serially diluted Pan10 (0.1–0 mg/
mL, free or conjugated) in 1% BSA/PBS were added to the plate.
Significance One of the cell-free rows was incubated with Pan10 while the other
lacked Pan10. The plate was then incubated for 1 hr at 37	C and
subsequently washed ten times with distilled water. Aliquots (30 L)We have shown that chemically modified anti-integrin
of M2 anti-flag/HRP (1.1 g/mL, Sigma) in 1% BSA/PBS were added31 scFv Pan10 containing free thiols can be conve-
to all the wells, and the plate was incubated for 1 hr at 37	C. Finally,niently conjugated to maleimide-derivatized analogs
following extensive washing with distilled water, the plate was devel-
of the potent cytotoxic agent duocarmycin SA. Our oped in the presence of TMB and H2O2 (Pierce, Rockford, IL) and
Pan10 conjugates conserve their ability to penetrate read at 450 nm with a Spectra Max 250 plate reader (Molecular
Devices, Sunnyvale, CA).cells expressing integrin31. In particular Pan10-drug
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Pan10 Mutation
Mutants Pan10S73C and Pan10S131C were generated by site-
directed mutagenesis on template pETflag-Pan10 using standard PCR
techniques. The primers used (Qiagen, Valencia, CA, mutated bases
in italics) were the following. Forward (5-end) primers: Pan10S73C,
5-AAGGGCAGGGCCACACTGTGTGTAGA-3; Pan10S131C, 5-GGA
GGTGGCTGCGGCGGTGGC-3. Reverse (3-end) primers: Pan-
10S73C, 5-CTACACACAGTGTGGCCCTGCCCTT-3; Pan10S131C,
5-GCCACCGCCGCAGCCACCTCC-3. The mutagenesis procedure
consisted of three stages. In the first, one end-primer (either forward
ARAHF, 5-GCCTACGGCAGCCGCTGGATTGTTATTACT-3, or re-
verse FLAG, 5-CTGGCAAGCTTATTATTTGTCATCGTCATCTTTGTA
GTC-3) and either one of the afore mentioned mutation primers
were combined to introduce the mutation (temperature program
[Mastercycler, Epperdorf, Hamburg, Germany]: denaturation at 95	C
for 10 min; 30 cycles of amplification; extension 2 min, 72	C; denatur-
ation, 95	C, 30 s; annealing 60	C, 1 min and polishing, 72	C, 7 min).
In the second stage, the two halves of the mutated genes were
overlapped (temperature program: denaturation at 95	C for 10 min;
20 cycles of amplification; extension 2 min, 72	C; denaturation, 95	C,
30 s; annealing 50	C, 1 min and polishing, 72	C, 7 min). Finally, in
the third stage, the product of overlap PCR was amplified using the
two end primers (temperature program: denaturation at 95	C for 10
min; 30 cycles of amplification; extension 2 min, 72	C; denaturation,
95	C, 30 s; annealing 55	C, 1 min and polishing, 72	C, 7 min). The
amplified products were purified with PCR purification kit (Qiagen),
digested with SfiI (New England BioLabs, Beverly, MA), purified,
and ligated (T4 DNA ligase, New England BioLabs) to SfiI-digested
and purified pETflag. The sequence the Pan10 mutants was con-
firmed by full-length DNA sequencing (The Protein and Nucleic Acids
Core Facility at The Scripps Research Institute, La Jolla, CA) using
the end-primers.
Pan10 Thiolation
Pan10 (4 mg/mL) in 50 mM triethanolamine, 1 mM EDTA, and 150
mM NaCl (pH 8.7) was incubated in the presence of a 10-fold stoi-
chiometric excess of Traut’s reagent (Pierce) for 5 hr at 4	C, under
constant agitation. The resultant mixture was desalted using PD-
10 columns (Pharmacia, Peapack, NJ), eluted with 50 mM HEPES
(pH 8) and concentrated by centrifugal ultrafiltration (YM 10,000
filter, Millipore). The concentration of free thiol in the desalted scFv
solution was determined by Ellman’s assay.
Figure 5. Schematic for the Synthesis of Boc-Protected 2
Ellman’s Assay
A 75% methanol solution of 30 M thiolated scFv or standard water (40 mL), dried (Na2SO4), and concentrated in vacuo. Flash
dithiotreitol (DTT, ICN, Costa Mesa, CA) and 600 mM 5,5-dithio- chromatography (silica gel, 0%–50% ethyl acetate/hexane) afforded
bis-(2-nitrobenzoic acid) (Ellman’s reagent, Sigma) was centrifuged 5 in 62% yield.
at 13,000 rpm for 5 min. The supernatant was transferred to a 96- Methyl 1-[3-(t-Butyloxycarbonyl)aminopropyl]indole-2-carboxyl-
well ELISA plate (Fisher, Ottawa, Ontario), and the Abs412 was read ate (6). A suspension of 5 (500 mg, 1.39 mmol) in ethanol (14 mL)
in a Spectra Max 25 plate reader (Molecular Devices). The concen- at 0	C was treated with hydrazine (200 L, 4.14 mmol). The reaction
tration of free thiols was extrapolated from a standard curve ob- mixture was stirred at 0	C for 1 hr and then allowed to warm to 25	C
tained by plotting known concentrations of DTT versus the corre- over 3 hr before being concentrated in vacuo. The residue dissolved
sponding Abs412. in chloroform (10 mL) was treated with t-butoxycarbonyl anhydride
(602 mg, 2.76 mmol) and saturated aqueous sodium carbonate (10
mL). The reaction mixture was stirred at 25	C for 12 hr before beingSynthesis of the Analogs of Duocarmycin SA
All the chemicals utilized were purchased from Aldrich (St. Louis, extracted with chloroform (3 
 100 mL). The combined organic
layers were dried (Na2SO4) and concentrated in vacuo. Flash chro-MO). Note that the characterization of all the synthetic compounds is
included as Supplemental Data. The synthesis of 3-(5-acetylindole- matography (silica gel, 10%–30% ethyl acetate/hexane) afforded 6
in 91% yield.2-carbonyl)-1-(S )-(chloromethyl)-5-hydroxy-1,2-dihydro-3H-
benz[e]indole (1) has been previously reported [51]. The synthesis Ethyl 5-(1-{3-[N-(t-Butyloxycarbonyl)amino]propyl}indole-2-car-
bonyl)-aminoindole-2-carboxylate (8). A solution of 6 (332 mg, 1.0of the Boc-protected 3-[5-(1-(3-aminopropyl)indole-2-carbonyl)
aminoindole-2-carbonyl]-1-(chloromethyl)-5-hydroxy-1,2-dihydro- mmol) in 10 ml dioxane/H2O (4:1) was treated with 4 N LiOH (1 mL),
and the mixture was stirred at 25	C for 15 hr. Aqueous HCl (1 N) (103H-benz[e]indole (10) is as follows (refer to Figure 5).
Methyl 1-(3-Phthalimidopropyl)indole-2-carboxylate (5). A solu- mL) was added, and the mixture was extracted with ethyl acetate
(3 
 50 mL). The combined organic layers were dried (Na2SO4), andtion of methyl indole-2-carboxylate (550 mg, 3.14 mmol) in dimethyl-
formamide (31 mL) at 0	C was treated with sodium hydride (60% concentrated in vacuo to give 7 in 92% yield.
A solution of 7 (63.6 mg, 0.2 mmol) and ethyl 5-aminoindole-2-suspension in mineral oil, 167 mg, 4.18 mmol) and allowed to warm
at 25	C over 30 min. The reaction mixture was cooled to 0	C and carboxylate (61.3 mg, 0.3 mmol) in dimethylformamide (4 mL) was
treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydro-treated with N-(3-bromopropyl)phthalimide (1.26 g, 4.71 mmol). The
mixture was allowed to warm at 25	C over 30 min and warmed at chloride (115 mg, 0.6 mmol). The reaction mixture was stirred at
25	C for 18 hr and quenched with the addition of 15% aqueous55	C for 30 min before being cooled and quenched with the addition
of H2O (30 mL). The reaction mixture was extracted with ethyl acetate citric acid (10 mL). The reaction mixture was extracted with ethyl
acetate (75 ml and 2 
 25 mL), the combined organic layers were(2 
 40 mL), and the combined organic layers were washed with
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washed with saturated aqueous NaCl (3 
 10 mL), dried (Na2SO4), % conjugation to drug  100  {Abs492/59880 

and concentrated in vacuo. Flash chromatography (silica gel, 33%
100/[Abs280  (0.2 
 Abs492)]/1.35/scFv-FM MW} (2)ethyl acetate/hexane) afforded 8 in 52% yield.
5-(1-{3-[N-(t-Butyloxycarbonyl)amino]propyl}indole-2-carbonyl)-
indole-2-carboxylic Acid (9). A solution of 8 (50.5 mg, 0.1 mmol) in Mass Spectrometry
2 ml dioxane/H2O (4:1) was treated with 4 N LiOH (200 L), and the MALDI-MS was performed on a Voyager DE Biospectrometry Work-
mixture was stirred at 25	C for 18 hr. Aqueous HCl (0.5 N) (5 mL) station (PerSeptive Biosystems, Framingham, MA) in the linear mode
was added, and the mixture was extracted with ethyl acetate (2 
 using a nitrogen laser (337 nm) and sinapinic acid (Sigma) as matrix.
30 mL). The combined organic layers were dried (Na2SO4) and con- Matrix solutions were prepared fresh daily as saturated solutions
centrated in vacuo. Crystallization from tetrahydrofuran/hexane af- in a 1:1 mixture of acetonitrile and 0.1% aqueous trifluoroacetic
forded 9 in 92% yield. acid. Samples were prepared for MALDI-MS analysis by diluting the
3-[5-(1-{3-[N-(t-Butyloxycarbonyl)amino]propyl}indole-2-carbonyl) desalted protein solution 1:10 with matrix and depositing 0.7 l of
aminoindole-2-carbonyl]-1-(chloromethyl)-5-hydroxy-1,2-dihydro- the resulting suspension directly onto a stainless steel MALDI target
3H-benz[e]indole (10). A solution of (–)-seco-N-Boc-CBI [60] (25 mg, well. The obtained masses were calibrated using two-point external
75 mol, natural enantiomer) in 10 ml 4 N HCl (ethyl acetate) was calibration with equine cytochrome C and rabbit muscle aldolase
stirred for 1 hr at 25	C before the solvent was removed under a (Sigma). All spectra were collected in positive ion mode with 140
stream of N2. The residue was dried under high vacuum for 3 hr and ns delayed extraction and summed over approximately 50 laser
9 (39.5 mg, 83 mol) was added. A solution of 1-(3-dimethylamino- shots.
propyl)-3-ethylcarbodiimide hydrochloride (43 mg, 225 mol) in di-
methylformamide (2 mL) was added, and the reaction mixture was One-Pot Antibody Conjugation
stirred for 14 hr at 25	C before the reaction mixture was concen- Pan10 (4 mg/mL) in 50 mM triethanolamine, 1 mM EDTA, and 150 mM
trated in vacuo. Flash chromatography (silica gel, 20% tetrahydrofu- NaCl (pH 8.7) was incubated 8 hr at 4	C, under constant agitation, in
ran/hexane) afforded 10 in 44% yield. the presence of a 10-fold stoichiometric excess of Traut’s reagent
(Pierce) and an equal excess of either fluorescein maleimide (Molec-
ular Probes), 3, or 4. The resultant mixture was desalted using PD-
Synthesis of 3 10 columns, eluted with PBS, and concentrated by centrifugal ultra-
A mixture of 1 (3.0 mg, 7.2mol), maleimidopropionic acid hydrazide filtration (YM 10,000 filter, Millipore) to 4 mg/mL.
tetrahydrofuran salt (6 mg, 20 mol), tetrahydrofuran (1 L), and
crushed 3 A˚ molecular sieves in 0.2 ml dimethylformamide was Confocal Microscopy
stirred overnight. Upon solvent evaporation the residue was dis- SW1990 or HdFa cells were trypsinized, resuspended in PBS, and
solved in dichloromethane and purified by silica gel thin layer chro- counted. Cells (104–105) were seeded into the wells of a chamber
matography. 3 was obtained in 47% yield. slide (Nunc, Naperville, IL) and allowed to attach for 24 hr at 37	C.
Upon changing the medium (500 L/well), 10 l of 3 mg/mL con-
centrated Pan10-fluorescein or 92H2-fluorescein (negative control)
Synthesis of 4 was added, and the cells were incubated for 30 min, 1, 2, or 3 hr
Compound 10 (5 mg, 7.2 mol) was treated with 50% trifluoroacetic at 37	C. The cells were then washed ten times with their respective
acid in dichloromethane for 30 min. Upon trifluoroacetic acid evapo- medium and once with PBS, then they were fixed and permeabilized
ration, the crude free amine was dissolved in 0.1 ml dimethylform- with 95% ethanol for 5 min, washed once with PBS, stained with
amide and added to a dimethylformamide solution containing malei- propidium iodine (Sigma, 1:50 diluted in PBS) for 1 min, washed five
midopropionic acid (2.0 mg, 12 mol), O-benzotriazol-1-yl-N, N, times with PBS, and sealed with a coverslip upon addition of antifade
N, N-tetramethyluronium hexafluoro-phosphate (4.2 mg, 11 mmol), solution (Slow Fade, Molecular Probes). The slides were observed
and N-methylmorpholine (3.2 L, 29 mol). The mixture was stirred with a laser scanning confocal microscope (MRC1024, Bio-Rad).
for 2 hr, and the solvent was evaporated. The residue was purified
by silica gel thin layer chromatography. 4 was obtained in 57% yield. FACS Analysis
SW1990 or HdFa cells were trypsinized, washed in cold PBS, and
aliquoted (5 
 105 cells/tube). The primary antibody (either W6/
Conjugation of Thiolated Pan10 32, Novus Biologicals, Littleton, CO; P1B5, Chemicon, Temecula,
Aliquots (1 l, 20 mM) of either fluorescein maleimide (Molecular CA; or P5D2, Chemicon) was then added (final concentration 10
Probes, Eugene, OR), 3, or 4 in DMSO were added to 50 l of Pan10 g/mL), and the incubation was carried on for 45 min on ice. The
(4 mg/mL in 50 mM HEPES) at intervals of 2 min. The resultant cells were then washed with cold PBS and incubated in the presence
reaction mixture was incubated on a shaker for 10 hr at 4	C. Free of FITC-labeled goat anti-mouse Ab (Pierce, Rockford, IL) on ice for
dye or free drug were separated from the mixture of conjugated 45 min. A final wash with cold PBS was followed by PI counterstain
Pan10 and free Pan10 by size-exclusion chromatography (PD-10 and analysis (FACScan, Becton Dickinson, Franklin Lakes, NJ).
column, Pharmacia). The percentage yield of Pan10 conjugation
to fluorescein was calculated by fitting the Abs492nm and Abs280nm Inverted Microscopy
(Ultrospec 2000, Pharmacia) of the desalted mixture into Equation 1: SW1990 cells were trypsinized, resuspended in PBS, and counted.
Cells (104–105) in 500 l of growth medium were seeded into the
wells of a chamber slide (Nunc) and allowed to attach for 24 hr at% conjugation to FM  Abs492/59880a 

37	C. The old medium was than replaced by medium containing
100/[Abs280  (0.2b 
 Abs492)]/1.35c/scFv-FM MW (1) 400 nM of either Pan10-3, Pan10-4, Pan10-FM, or wt-Pan10. Cells
were then observed with an inverted microscope (Zeiss Imm,
Thornwood, NY) every day for 7 days.a492 experimentally determined for FM; bAbs280/Abs492 experimentally
determined for FM; cantibody 280.
The ratio of 3 or 4 to scFv was indirectly determined by calculating Cell Proliferation Assay
The cytotoxicity of scFv-drug or free drug was quantified by usingthe amount of residual free scFv after the drug conjugation step.
The mixture of Pan10-drug conjugate and free Pan10 was reacted the Vybrant MTT cell proliferation assay kit (Molecular Probes).
Assays were performed using 48-well microtiter plates containingwith fluorescein-maleimide, and the amount of fluorescein-Pan10
(determined as described above) was assumed to correspond to 2 
 104 SW1990(HdFa) cells/well in 300 l of phenol-free growth
medium. Cells were allowed to attach to the wells for 12 hr. Forthe entire amount of Pan10 not bound to the drug. The percentage
yield of Pan10 conjugation to 3 or 4 was calculated by fitting the determination of IC50, cells were incubated for 3 or 12 hr at 37	C
with various concentrations of Pan10-drug conjugates, maleimideAbs492 nm and Abs280nm of the desalted mixture obtained after the
conjugation of scFv-drug  free scFv to the maleimide derivative derivatives, or free drugs. Then the incubation was continued in
conjugate/drug-free medium, and the MTT assay was performed atof fluorescein into Equation 2:
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the end of the seventh day. Medium was replaced with 100 l of antibody drug immunoconjugates for targeted treatment of can-
cer. Cancer Immunol. Immunother. 52, 328–337.fresh medium containing 1.2 mM MTT and the incubation continued
for 3 more hours. The cells were then lysed by adding 100 l of a 9. Gao, C., Mao, S., Ronca, F., Zhuang, S., Quaranta, V., Wirsching,
P., and Janda, K.D. (2003). De novo identification of tumor-10 mM solution of HCl containing SDS (100 mg/mL). The cell lysis
was allowed to proceed for a period of 8 hr at the end of which the specific internalizing human antibody-receptor pairs by phage-
display methods. J. Immunol. Methods 274, 185–197.plate was centrifuged at 3000 rpm for 3 min and the supernatant
transferred in a 96-well plate and read at 570 nM. Each assay in- 10. Gao, C., Mao, S., Ditzel, H.J., Farnaes, L., Wirsching, P., Lerner,
R.A., and Janda, K.D. (2002). A cell-penetrating peptide from acluded a negative control of cells treated with free Pan10 and a
positive control lacking cells. All assays were performed at least novel pVII-pIX phage-displayed random peptide library. Bioorg.
Med. Chem. 10, 4057–4065.twice. A set of eight data points was obtained with various concen-
tration of cytotoxicity agent. In order to obtain the IC50 values, data 11. Hamann, P.R., Hinman, L.M., Beyer, C.F., Lindh, D., Upeslacis,
J., Flowers, D.A., and Bernstein, I. (2002). An anti-CD33 anti-points from each set were fit to the sigmoidal dose-response curve
defined by Equation 3 using Grafit5 (Leatherbarrow, R.J. 2003. Grafit body-calicheamicin conjugate for treatment of acute myeloid
leukemia. Choice of linker. Bioconjug. Chem. 13, 40–46.version 5.08, Erithieus Software Ltd, Staines, England).
12. Elices, M.J., Urry, L.A., and Hemler, M.E. (1991). Receptor func-
y  ymin  {(ymax  ymin)/[1  (IC50/x)slope]} (3) tions for the integrin VLA-3: fibronectin, collagen, and laminin
binding are differentially influenced by Arg-Gly-Asp peptide and
y  percent of live cells; x  concentration of drug (drug-scFv). by divalent cations. J. Cell Biol. 112, 169–181.
Data points which were outliers (typically one to two per experi- 13. Melchiori, A., Mortarini, R., Carlone, S., Marchisio, P.C., Anichini,
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